CDXC (ChromaDex Corp) צמיחת רווח נקי למניה השנה

The innovative cellular health supplement market is expanding rapidly, opening global distribution channels for ChromaDex Corporation (CDXC). The annual EPS growth trajectory visualizes this trend, where 18.40 represents the latest level. The company generates revenue from supplying longevity ingredients, leveraging exclusive Niagen synthesis patents and strict FDA oversight, which creates significant barriers to entry for new players.
פילוחים אנליטיים ודוחות נתונים של חברת ChromaDex Corp (CDXC)

To assess the issuer's financial stability, it is critical to analyze the year-over-year dynamics of net earnings per share. This metric measures the rate of change in return on equity, making it possible to identify risks of undervaluation or excessive corporate leverage. Amid intense competition in the dietary supplement sector, the annual earnings per share trajectory on GURU.Markets demonstrates the ability of ChromaDex Corporation (CDXC) to monetize its scientific research.